Wren Therapeutics has developed oral small molecules that suppress the production of toxic alpha-synuclein protein forms in cellular and mouse models used to study Parkinson’s disease. The potential first-in-class molecules were designed with Wren’s technology platform to hinder processes involved in the generation of alpha-synuclein oligomers, the…
Blocking the activity of the synuclein nitrase enzyme reduced the levels of toxic clumps of the alpha-synuclein protein and lessened paralysis in mouse models of Parkinson’s disease, according to new data from Nitrase Therapeutics. Formation of toxic aggregates of alpha-synuclein is a hallmark of Parkinson’s and “has been…
PharmaTher Holdings has received guidance from the U.S. Food and Drug Administration (FDA) on the late-stage clinical development of ketamine for levodopa-induced dyskinesia, or uncontrolled movements, in people with Parkinson’s disease. “We are satisfied with the feedback we received from the Type C meeting with the FDA, which lays…
A science team at Merck (known as MSD outside North America) is the winner of an $8.5 million competition to develop an imaging technology capable of visualizing alpha-synuclein protein in the brains of people living with Parkinson’s disease, the contest’s organizer, The Michael J. Fox Foundation for Parkinson’s…
Athira Pharma is completing its Phase 2 clinical trial of the experimental therapy fosgonimeton in people with Parkinson’s disease dementia or dementia with Lewy bodies with fewer participants than its initial target enrollment. According to a recent corporate update, the company has closed recruitment with 28 of…
Women who undergo surgery to remove both of their ovaries before age 43 have a five times higher risk of developing Parkinson’s disease in the future, according to a U.S. study. For younger women who had the procedure, called a bilateral oophorectomy, use of estrogen replacement therapy until the…
A Phase 2 clinical trial of Neuraly’s NLY01 failed to show the experimental therapy was superior to a placebo at significantly slowing motor symptom progression in adults with early and untreated Parkinson’s disease. Some promising trends among patients younger than 60 were seen following analyses of the trial’s…
NeuroRPM, an artificial intelligence (AI)-powered app designed to continuously monitor hallmark symptoms of Parkinson’s disease has been cleared for use by the U.S. Food and Drug Administration (FDA). “The clearance of NeuroRPM is a major milestone in the fight against Parkinson’s disease,” Alexander Ksendzovsky, MD, PhD, cofounder and chief…
While dopamine-replacing therapies are a key component of Parkinson’s disease care, they only reflect a person’s physical characteristics or the state of their disease. Adding a dose of “hopamine” — a person’s own unique set of hopes, desires, experiences, and skills — to Parkinson’s care takes patients’ personal characteristics…
Note: This story was updated March 24, 2023, to correct the name of CND Life Sciences. CND Life Sciences has signed a licensing and collaboration agreement with Beth Israel Deaconess Medical Center (BIDMC) in Boston to develop minimally invasive, diagnostic tests for Parkinson’s and other neurodegenerative diseases. The…
Get regular updates to your inbox.